Valuation: GENFIT

Market Cap 715M 0 825M 668M 613M 1.16B 78.67B 1.17B 7.85B 3.07B 39.25B 3.1B 3.03B 130B P/E 2026 *
36.9x
P/E 2027 * 95x
Enterprise Value 664M 0 766M 620M 569M 1.08B 73.05B 1.09B 7.29B 2.85B 36.44B 2.88B 2.81B 121B EV / Sales 2026 *
6.63x
EV / Sales 2027 * 5.23x
Free-Float
86.88%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 58 16/09/2019
Director of Finance/CFO 52 22/04/2021
Chief Tech/Sci/R&D Officer - 27/11/2025
Director TitleAgeSince
Chairman 70 16/06/2017
Director/Board Member 54 15/09/1999
Director/Board Member 58 16/06/2017
Change 5-day change 1-year change 3-year change Capi.($)
-0.68%-0.54%-2.73%+13.55% 48.22B
+6.03%+2.87%+428.15%+506.65% 38.79B
-2.21%+7.03%+25.08%+5.51% 38.41B
+2.94%-0.89%+8.03%+56.94% 34.88B
+1.98%+3.97%+13.89%+40.90% 29.19B
+0.31%-2.42%+35.92%+122.86% 16B
+0.47%-3.48% - - 16.05B
+1.59%+2.84%+4.40%+16.88% 13.53B
-0.98%-7.07%-5.76%-37.52% 12.22B
Average +0.40%-0.61%+63.37%+90.72% 27.48B
Weighted average by Cap. +0.29%+0.21%+80.81%+109.98%

Financials

2026 *2027 *
Net sales 100M 0 116M 93.5M 85.9M 162M 11.02B 164M 1.1B 430M 5.5B 434M 424M 18.22B 124M 0 143M 116M 106M 201M 13.64B 203M 1.36B 533M 6.81B 537M 525M 22.56B
Net income 22.88M 0 26.38M 21.35M 19.61M 37.1M 2.52B 37.43M 251M 98.24M 1.26B 99.07M 96.86M 4.16B 6.8M 0 7.84M 6.35M 5.83M 11.03M 748M 11.13M 74.62M 29.2M 373M 29.45M 28.79M 1.24B
Net Debt -51.12M -0 -58.95M -47.7M -43.82M -82.9M -5.62B -83.63M -561M -220M -2.8B -221M -216M -9.3B -66.17M -0 -76.31M -61.75M -56.73M -107M -7.28B -108M -726M -284M -3.63B -287M -280M -12.04B
Logo GENFIT
GENFIT is a biopharmaceutical company in late-stage development focused on the discovery and development of innovative therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, in particular due to a lack of approved treatments. GENFIT is a leading innovator in the field of nuclear receptor-based drug discovery with a rich history and a solid scientific heritage spanning nearly two decades. The company has offices in Lille, Paris, Zurich and Cambridge, MA (USA).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-